Braeburn is developing long-acting medicines for treating opioid addiction.
Opioid addiction is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines allow patients to focus on the reintegration of their lives and communities. Braeburn’s products are positioned to provide a key solution in treating OUD (opioid use disorder). Because Braeburn’s long acting formulations are intended to be administered by the health care provider, there are significant opportunities to treat OUD without risks of abuse and diversion.
PRODUCTS AND PIPELINE
Braeburn develops next generation pharmaceuticals for opioid addiction treatment.
The focus of Braeburn is primarily on opioid dependence but it is also our aim to address other therapeutic areas in pain where our competence and technologies can create value.
Our robust product pipeline targets opioid use disorder, with CAM2038 weekly and CAM2038 monthly formulations. CAM2038 is a subcutaneous injection depot formulation of buprenorphine. CAM2038’s proprietary FluidCrystal® delivery system enables a gel-like encapsulation of buprenorphine under the skin which allows for release over a period of a week or a month.
Probuphine® (buprenorphine) is a 6 month buprenorphine subdermal implant, approved by the FDA in May 2016. Probuphine is the first and only product on the market for opioid use disorder that provides non-fluctuating blood levels of buprenorphine around the clock for a period of six months following a single treatment procedure.
450 Plymouth Rd, Suite 400
Plymouth Meeting, PA 19462